Navigation Links
Sorafenib Shows Promise for Heart-Lung Disease
Date:5/20/2008

Cancer drug interferes with abnormal cell growth seen in pulmonary hypertension

TUESDAY, May 20 (HealthDay News) -- The cancer drug sorafenib (Nexavar) shows promise as a treatment for pulmonary hypertension, according to a University of Chicago Medical Center study.

During the study, nine patients took the drug for 16 weeks at doses lower than those given to cancer patients. The patients also continued to take their standard medications.

Eight of the patients increased their ability to exercise, six showed significant improvements in their right ventricular ejection fraction (the ability of the heart to pump blood to the lungs), and four had a significant decrease in pulmonary artery pressures.

The most common side effects were diarrhea and hair loss.

The findings were expected to be presented May 20 at the American Thoracic Society annual meeting, in Toronto.

"This is not a disease where we are used to seeing people who have been stable on the strongest medications we have suddenly get better. We have drugs that may slow progression of the disease, but nothing that can stop or reverse the process," study author Dr. Mardi Gomberg-Maitland, an assistant professor of medicine, said in a prepared statement.

"To see these improvements in such a short time is quite promising. Although evaluation of this drug is at a very early stage, and this study focused on safety and tolerability, we are genuinely excited about the results," Gomberg-Maitland said.

Sorafenib was originally developed at the University of Chicago as a treatment for kidney cancer. Both cancer and pulmonary hypertension involve abnormal cell growth. In pulmonary hypertension, the abnormal cell growth occurs in blood vessels that lead to the lungs, causing the vessels to thicken and narrow. This means the heart has to work harder to pump blood to the lungs. This extra workload damages the heart.

Sorafenib appears to interfere with the abnormal cell growth seen in pulmonary hypertension.

Researchers are now organizing a multi-center trial of the drug in patients with pulmonary hypertension.

More information

The U.S. National Heart, Lung, and Blood Institute has more about pulmonary hypertension.



-- Robert Preidt



SOURCE: University of Chicago Medical Center, news release, May 19, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Sorafenib Slows Growth of Some Leukemias
3. With age comes a sense of peace and calm, population research center study shows
4. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
5. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
6. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
7. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
8. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
9. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
10. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
11. Research shows HPV testing offers women protection for twice as long as smear testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: